YOLFTbeta
Asymchem Laboratories Tian Jin Co Ltd

Asymchem Laboratories Tian Jin Co Ltd

002821 · SHE · Healthcare / Biotechnology

147.41CNY-5.27 (-3.45%)

Price History

Full chart

Market Stats

Previous Close152.68
Open151.00
Day Range146.85 – 152.46
52-Week Range87.70 – 200.00
Volume6.77M
Market Cap68.27B
P/E (TTM)64.60
Forward P/E0.00
EPS2.92
Dividend Yield0.69%
Beta0.13
50-Day Avg169.87
200-Day Avg129.07

About

Asymchem Laboratories (Tianjin) Co., Ltd. provides contract development and manufacturing organization (CDMO) solutions in Mainland China and internationally. It is involved in small molecule CDMO services for projects covering multiple major disease treatment areas, such as oncology, antiviral, anti-infective, cardiovascular, and diabetes; chemical macromolecule CDMO; biomacromolecule CDMO, including antibody-peptide conjugates; formulation CDMO; clinical CRO; synthetic biology and new technology output business. The company also engages in key pharmaceutical intermediates, APIs, and formulations activities. The company was founded in 1998 and is headquartered in Tianjin, China.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Hao Hong Ph.D.
  • Employees10.62K
  • HeadquartersNo. 71, Seventh Avenue, Tianjin, China, 300457, China
  • Websitehttps://www.asymchem.com.cn

Leadership

  • Dr. Hao Hong Ph.D.Founder, Chairman & CEO · b. 1956
  • Ms. Rui YangCo-CEO & Executive Director · b. 1977
  • Mr. Da ZhangCFO, COO, Senior VP & Executive Director · b. 1981
  • Mr. Jiang YingweiExecutive Vice President of Human Resources & Administration · b. 1977
  • Dr. Liang HongExecutive VP & Executive Director · b. 1974
  • Mr. Chaoyong ChenExecutive Vice President of Manufacturing & Tech Transfer · b. 1982
  • Dr. Yan ZhouSenior Vice President of Quality Management · b. 1979
  • Dr. Chen Yi ChengCTO of the Small-Molecule Sector · b. 1964
  • Mr. Xiangke XuSenior Vice President and Board Secretary of Public Affairs & Regulatory Affairs & Legal Affairs · b. 1979
  • Mo HuangAccounting Supervisor

Financials

Income Statement

Currency: CNY2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue405.69M424.40M542.76M716.21M830.61M1.10B1.42B1.83B2.46B3.14B4.63B10.23B7.83B5.80B6.67B
Growth (%)-+4.61%+27.89%+31.96%+15.97%+32.82%+28.99%+28.94%+34.07%+27.51%+47.67%+120.85%-23.51%-25.82%+14.91%
Cost of Revenue217.20M228.24M299.53M404.45M430.09M533.92M686.73M981.67M1.34B1.68B2.58B5.40B3.83B3.39B3.87B
Gross Profit188.49M196.16M243.23M311.76M400.52M569.28M736.30M853.20M1.12B1.45B2.05B4.83B3.99B2.41B2.80B
Gross Margin46.46%46.22%44.81%43.53%48.22%51.60%51.74%46.50%45.50%46.33%44.25%47.24%51.02%41.55%41.99%
Operating Expense111.31M122.25M156.27M190.52M200.06M254.36M316.71M391.82M495.73M685.85M981.81M1.72B1.42B1.33B1.55B
Operating Income77.18M73.91M86.96M121.24M200.46M314.92M419.59M461.39M623.67M767.37M1.07B3.11B2.57B1.08B1.25B
Operating Margin19.02%17.42%16.02%16.93%24.13%28.55%29.49%25.15%25.35%24.46%23.05%30.40%32.85%18.58%18.80%
EBITDA105.13M104.01M138.60M177.50M233.33M356.93M495.29M495.60M665.78M922.02M1.24B3.43B2.65B1.07B1.85B
EBITDA Margin25.91%24.51%25.54%24.78%28.09%32.35%34.81%27.01%27.06%29.39%26.83%33.56%33.83%18.43%27.74%
Net Income65.37M60.25M74.73M101.79M153.55M252.74M341.29M428.30M553.86M719.74M1.07B3.30B2.27B948.95M1.13B
Net Income Margin16.11%14.20%13.77%14.21%18.49%22.91%23.98%23.34%22.51%22.95%23.08%32.27%28.99%16.35%16.98%
R&D28.10M40.13M44.24M52.74M65.10M70.48M97.24M155.18M192.52M258.93M387.48M708.89M707.86M614.49M593.26M
R&D as % of Total Revenue6.93%9.46%8.15%7.36%7.84%6.39%6.83%8.46%7.83%8.25%8.37%6.93%9.05%10.59%8.89%
Interest Expense4.76M2.73M4.57M3.55M2.12M9.92M4.45M3.49M773.26K2.86M7.87M11.18M6.32M10.08M12.75M
Interest Expense % of Total Revenue1.17%0.64%0.84%0.50%0.25%0.90%0.31%0.19%0.03%0.09%0.17%0.11%0.08%0.17%0.19%

Balance Sheet

Currency: CNY2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets800.41M828.00M913.19M1.06B1.27B2.44B2.64B3.19B3.76B7.18B15.16B18.24B19.77B19.29B20.28B
Total Liabilities258.15M219.94M227.09M273.00M334.48M611.91M482.17M674.77M713.23M1.19B2.55B2.54B2.26B2.43B2.63B
Total Equity507.19M561.84M629.84M745.56M881.24M1.75B2.06B2.51B3.05B5.99B12.61B15.65B17.48B16.85B17.64B
Cash175.42M67.16M84.34M144.29M264.97M1.08B839.28M629.97M435.25M2.12B6.23B5.29B7.11B5.79B6.32B
Total Debt63.00M52.00M49.92M69.84M80.00M186.00M151.66M123.13M90.53M35.92M421.27M109.86M118.71M282.53M-
Net Debt-112.42M-15.16M-34.42M-74.45M-184.97M-897.58M-839.28M-629.97M-435.25M-2.09B-5.81B-5.18B-6.99B-5.51B-

Cash Flow

Currency: CNY2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow25.88M34.38M105.92M127.05M256.99M278.36M196.40M415.06M600.87M569.29M113.15M3.29B3.55B1.25B1.41B
Investing Cash Flow-145.54M-121.99M-77.11M-57.59M-140.57M-199.57M-300.28M-583.70M-699.90M-1.10B-2.21B-4.67B-2.69B-1.18B-
Financing Cash Flow240.88M-14.74M-10.18M-7.43M-13.22M682.08M-65.12M-42.70M-102.10M2.27B6.21B-742.53M-542.03M-1.93B-
Capital Expenditure137.32M132.17M91.73M67.49M123.22M236.37M303.40M543.16M510.75M1.01B1.66B2.15B1.24B1.13B1.27B
Free Cash Flow-111.44M-97.78M14.19M59.55M133.77M41.99M-107.00M-128.10M90.12M-445.67M-1.55B1.14B2.31B124.33M137.22M
Dividends Paid31.30M8.74M6.85M14.58M22.59M35.40M59.15M80.53M92.52M115.64M145.56M211.27M663.90M641.94M395.07M
FCF to OCF-430.54%-284.38%13.40%46.87%52.05%15.08%-54.48%-30.86%15.00%-78.28%-1366.85%34.57%65.02%9.91%9.75%
Dividend Paid to FCF-28.08%-8.94%48.31%24.49%16.89%84.31%-55.28%-62.87%102.67%-25.95%-9.41%18.59%28.76%516.32%287.90%

Earnings

Report DateMar 2, 2017Apr 24, 2017Aug 10, 2017Oct 23, 2017Feb 27, 2018Apr 19, 2018Aug 17, 2018Oct 30, 2018Feb 27, 2019Apr 22, 2019Aug 2, 2019Oct 24, 2019Feb 28, 2020Apr 25, 2020Aug 7, 2020Oct 23, 2020Dec 31, 2020Apr 22, 2021Aug 15, 2021Oct 26, 2021Mar 30, 2022Apr 20, 2022Aug 25, 2022Oct 27, 2022Mar 30, 2023Apr 28, 2023Aug 29, 2023Oct 30, 2023Mar 28, 2024Apr 25, 2024Aug 28, 2024Oct 29, 2024Apr 25, 2025Aug 26, 2025Oct 31, 2025Apr 28, 2026Aug 25, 2026
EPS Estimate----------------0.760.76----0.760.76-0.851.71-0.900.910.620.67-----
EPS Actual0.280.220.330.330.620.230.410.460.730.290.420.430.820.470.660.590.640.640.820.791.081.360.642.711.571.722.841.450.160.680.570.620.900.820.520.840.61
Surprise-----------------15.79%-15.79%-----15.79%256.58%-102.35%66.08%--82.22%-25.27%-8.06%-7.46%-----
TimingAfter-hoursPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-Pre-marketAfter-hoursPre-marketPre-marketAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market----

Key Statistics & Ratios

Market Cap68.27B
Enterprise Value60.08B
Trailing P/E64.60
Forward P/E0.00
Price / Sales9.63
Price / Book3.82
EPS2.92
Book Value49.89
Revenue (TTM)7.09B
Gross Profit (TTM)2.87B
EBITDA1.71B
Profit Margin14.61%
Operating Margin17.49%
Return on Equity5.90%
Return on Assets3.63%
Shares Outstanding334.11M
Shares Float217.30M
Beta0.13
Dividend Yield0.69%
Dividend Rate1.30
Payout Ratio66.16%

Dividends

20261×
1.30Jun 26, 2026
20251×
1.10Jun 26, 2025
20241×
1.80Jun 28, 2024
20231×
1.80Jun 28, 2023
20221×
0.80Jul 21, 2022
20211×
0.43Jul 13, 2021
20201×
0.36Jun 24, 2020
20191×
0.29Jun 10, 2019
20181×
0.25May 25, 2018
20171×
0.18Jun 14, 2017

Stock Splits

  • Jul 21, 20221.4:1
  • Jun 14, 201720:10